Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature
Open accessThe DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Abstract
Colorectal cancer is the third most common cancer worldwide with a high mortality rate at the advanced stages. However, colorectal cancer is not a single type of tumor; its pathogenesis depends on the anatomical location of the tumor and differs between right side and left side of the colon. Tumors in the proximal colon (right side) and distal colon (left side) exhibit different molecular characteristics and histology. In the right-sided tumors, mutations in the DNA mismatch repair pathway are commonly observed; and these tumors generally have a flat histology. In the left-sided tumors, chromosomal instability pathway-related mutations, such as KRAS, APC, PIK3CA, p53 mutations are observed and these tumors demonstrate polypoid-like morphology. Therapy responses are totally different between these tumor entities. Left-sided colorectal cancer (LCRC) patients benefit more from adjuvant chemotherapies such as 5-fluorouracil (5-FU)-based regimes, and targeted therapies such as anti- epidermal growth factor receptor (EGFR) therapy, and have a better prognosis. Right-sided colorectal cancer (RCRC) patients do not respond well to conventional chemotherapies, but demonstrate more promising results with immunotherapies because these tumors have high antigenic load. For the development of effective therapy regimes and better treatment options, it is essential to evaluate right-sided and left-sided tumors as separate entities, and design the therapy regime considering the differences between these tumors. Gastroenterol Res. 2018;11(4):264-273 doi: https://doi.org/10.14740/gr1062w
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Right-sided tumors more commonly exhibit DNA mismatch repair deficiencies, while left-sided tumors often have mutations in KRAS, APC, PIK3CA, and p53 [30].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“highly use these regulators as an anti-tumor immune response [82, 83].”
BackgroundA genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132 · cited 1×
“In this model, carcinogenesis begins with the inactivation or deletion of adenomatous polyposis coli (APC) tumor suppressor gene, followed by the activation of Kirsten ras homolog (KRAS) oncogene, the inactivation of p53 tumor suppressor gene and other mutations [47, 48].”
MethodPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Metastatic melanoma is one of the tumors with high immunogenic load and melanoma patients are highly benefiting from anti-CTLA-4 and anti-PD-1 therapies [87, 88].”
BackgroundGenetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728 · cited 1×
“In this model, carcinogenesis begins with the inactivation or deletion of adenomatous polyposis coli (APC) tumor suppressor gene, followed by the activation of Kirsten ras homolog (KRAS) oncogene, the inactivation of p53 tumor suppressor gene and other mutations [47, 48].”
MethodType, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 4×
“Presence of T cells in these tumors is associated with better prognosis and less frequent metastasis [12, 13, 24].”
BackgroundInfluentialImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · cited 1×
“Interestingly, tumor infiltrating lymphocytes express high level of PD-L1, which is thought to be a result of chronic stimulation because of the neoantigen load [86].”
BackgroundBoland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839 · cited 1×
“Metastatic melanoma is one of the tumors with high immunogenic load and melanoma patients are highly benefiting from anti-CTLA-4 and anti-PD-1 therapies [87, 88].”
BackgroundOverman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836 · cited 1×
“Nivolumab has shown promising results in MSI-high tumors [93].”
BackgroundBrenner, H., Kloor, M., & Pox, C. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61649-9 · Cited by 2,762
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · cited 1×
“CTLA-4 predominantly functions in the initial steps of immune activation, functioning in CD4+ T cells (regulator and effector T cells) for T cell priming and activation, whereas PD-L1 is either expressed by macrophages or tumors cells and interacts with CD8+ T cells [85].”
BackgroundMicrosatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160 · cited 4×
“Difference Between Right Sided and Left Sided Colorectal Tumor [5-20]”
BackgroundInfluentialColorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors
Haggar, F., & Boushey, R. (2009) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0029-1242458 · Cited by 2,011 · cited 4×
“Difference Between Right Sided and Left Sided Colorectal Tumor [5-20]”
BackgroundInfluentialMolecular Genetics of Colorectal Cancer
Fearon, E. R. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130235 · Cited by 1,805
Mechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383 · cited 1×
“Immune checkpoint inhibitors are antagonists, functioning by repressing inhibitory PD-1, PD-L1 and CTLA-4 receptor activities [84].”
BackgroundTowards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
Galon, J., Mlecnik, B., Bindea, G., Angell, H. K., Berger, A., Lagorce, C., Lugli, A., Zlobec, I., Hartmann, A., Bifulco, C., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4287 · Cited by 1,360 · cited 2×
“In the CIN pathway, high frequency of DNA copy number alterations, and non-hypermutated tumors are observed [40, 41].”
BackgroundRoth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,158 · cited 1×
“between KRAS mutations and overall survival [57].”
CpG island methylator phenotype in cancer
Issa, J.-P. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1507 · Cited by 1,098 · cited 1×
“BRAF mutations are also commonly observed with CIMP phenotype [42, 43].”
BackgroundVerwaal, V. J., Bruin, S., Boot, H., van Slooten, G., & van Tinteren, H. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9966-2 · Cited by 1,033 · cited 1×
“Historically peritoneal metastases had the worst outcome; however, with the advance in hyperthermic intraperitoneal chemotherapy (HIPEC), the survival rates have improved among this patient group [28].”
BackgroundGill, S., Loprinzi, C. L., Sargent, D. J., Thomé, S. D., Alberts, S. R., Haller, D. G., Benedetti, J., Francini, G., Shepherd, L. E., Francois Seitz, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.059 · Cited by 1,021
The Chromosomal Instability Pathway in Colon Cancer
Pino, M. S., & Chung, D. C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.065 · Cited by 932 · cited 2×
“Chromosomal instability is characterized by widespread imbalances in chromosome number (aneuploidy) and loss of heterozygosity (LOH) [25].”
BackgroundMoertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-5-199503010-00001 · Cited by 925 · cited 1×
“However, it should be emphasized that these adjuvant chemotherapies are mostly effective in the advanced stage (stage III and IV) patients after resection of tumors [73].”
BackgroundGenomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
Giannakis, M., Mu, X. J., Shukla, S. A., Qian, Z. R., Cohen, O., Nishihara, R., Bahl, S., Cao, Y., Amin-Mansour, A., Yamauchi, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.075 · Cited by 913 · cited 1×
“Presence of T cells in these tumors is associated with better prognosis and less frequent metastasis [12, 13, 24].”
BackgroundKirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study
Andreyev, H. J. N., Norman, A. R., Cunningham, D., Oates, J., Dix, B. R., Iacopetta, B. J., Young, J., Walsh, T., Ward, R., Hawkins, N., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1964 · Cited by 872 · cited 1×
“to have an effect on overall survival rates of CRC patients [56].”
BackgroundAre there two sides to colorectal cancer?
Iacopetta, B. (2002) · International Journal of Cancer · doi:10.1002/ijc.10635 · Cited by 782 · cited 5×
“Difference Between Right Sided and Left Sided Colorectal Tumor [5-20]”
BackgroundInfluentialKirsten ras mutations in patients with colorectal cancer: The multicenter “RASCAL” study
Andreyev, H. J. N., Norman, A. R., Clarke, P. A., Cunningham, D., & Oates, J. R. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.9.675 · Cited by 748 · cited 1×
“was shown to be associated with higher mortality [55].”
BackgroundPetrelli, F., Tomasello, G., Borgonovo, K., Ghidini, M., Turati, L., Dallera, P., Passalacqua, R., Sgroi, G., & Barni, S. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4227 · Cited by 729 · cited 1×
“However, most of the studies have shown that the prognosis of RCRC is worse than that of LCRC [29-31].”
BackgroundBRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum
Kambara, T., Simms, L. A., Whitehall, V. L. J., Spring, K. J., Wynter, C. V. A., Walsh, M. D., Barker, M. A., Arnold, S., McGivern, A., Matsubara, N., et al. (2004) · Gut · doi:10.1136/gut.2003.037671 · Cited by 722 · cited 1×
“BRAF mutations are also commonly observed with CIMP phenotype [42, 43].”
BackgroundBenedix, F., Kube, R., Meyer, F., Schmidt, U., Gastinger, I., & Lippert, H. (2010) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e3181c703a4 · Cited by 713
Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery
Macůrek, L., Lindqvist, A., Lim, D., Lampson, M. A., Klompmaker, R., Freire, R., Clouin, C., Taylor, S. S., Yaffe, M. B., & Medema, R. H. (2008) · Nature · doi:10.1038/nature07185 · Cited by 710 · cited 1×
“For example, dysregulated expression of Aurora B and PLK highly correlated with CIN phenotype and advanced stages of CRC [49-51].”
BackgroundTejpar, S., Stintzing, S., Ciardiello, F., Tabernero, J., Van Cutsem, E., Beier, F., Esser, R., Lenz, H.-J., & Heinemann, V. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3797 · Cited by 709 · cited 1×
“The same results were obtained with CRYSTAL and FIRE trials as well [77].”
ResultFamilial adenomatous polyposis
Half, E., Bercovich, D., & Rozen, P. (2009) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-4-22 · Cited by 596
Protection From Right- and Left-Sided Colorectal Neoplasms After Colonoscopy: Population-Based Study
Brenner, H., Hoffmeister, M., Arndt, V., Stegmaier, C., Altenhofen, L., & Haug, U. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp436 · Cited by 573 · cited 1×
“Right-sided CRC tumors are still detectable at an early stage, but with much more difficult than LCRC tumors because of their flat morphology [98, 99].”
BackgroundPD-1 blockade in tumors with mismatch repair deficiency.
Le, D. T., Uram, J. N., Wang, H., Bartlett, B., Kemberling, H., Eyring, A., Skora, A., Azad, N. S., Laheru, D. A., Donehower, R. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.lba100 · Cited by 565
Is There a Difference in Survival between Right- versus Left-Sided Colon Cancers?
Meguid, R. A., Slidell, M. B., Wolfgang, C. L., Chang, D. C., & Ahuja, N. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0015-y · Cited by 546 · cited 6×
“Difference Between Right Sided and Left Sided Colorectal Tumor [5-20]”
BackgroundInfluentialHolch, J. W., Ricard, I., Stintzing, S., Modest, D. P., & Heinemann, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.007 · Cited by 534
TGF- : Duality of Function Between Tumor Prevention and Carcinogenesis
Principe, D. R., Doll, J. A., Bauer, J., Jung, B., Munshi, H. G., Bartholin, L., Pasche, B., Lee, C., & Grippo, P. J. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt369 · Cited by 523 · cited 1×
“Although it has a growth-suppressive function in the initial stages of tumorigenesis, it contributes to metastasis in the advanced stages [63].”
BackgroundSystemic Treatment of Colorectal Cancer
Wolpin, B. M., & Mayer, R. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.098 · Cited by 504
Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
Loupakis, F., Yang, D., Yau, L., Feng, S., Cremolini, C., Zhang, W., Maus, M. K. H., Antoniotti, C., Langer, C., Scherer, S. J., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju427 · Cited by 472 · cited 1×
“However, most of the studies have shown that the prognosis of RCRC is worse than that of LCRC [29-31].”
BackgroundMutations Associated with HNPCC Predisposition — Update of ICG‐HNPCC/INSiGHT Mutation Database
Peltomäki, P., & Vasen, H. (2004) · Disease Markers · doi:10.1155/2004/305058 · Cited by 437 · cited 2×
“While RCRC tumors tend to be MSI-high, LCRC tumors are CIN-high tumors [27, 44-46].”
BackgroundMolecular pathological classification of colorectal cancer
Müller, M. F., Ibrahim, A. E. K., & Arends, M. J. (2016) · Virchows Archiv · doi:10.1007/s00428-016-1956-3 · Cited by 432
Ogino, S., Nosho, K., Irahara, N., Meyerhardt, J. A., Baba, Y., Shima, K., Glickman, J. N., Ferrone, C. R., Mino-Kenudson, M., Tanaka, N., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1438 · Cited by 418
(2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.104 · Cited by 389 · cited 1×
“Among the metastatic CRC patients administered with fluorouracil and leucovorin, 20% had reduction in tumor size and showed an increment in overall survival from 6 months to 12 months [71, 72].”
BackgroundBRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing
Domingo, E., Laiho, P., Ollikainen, M., Pinto, M., Wang, L., French, A. J., Westra, J., Frebourg, T., Espín, E., Armengol, M., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.020651 · Cited by 339 · cited 4×
“A third mechanism, CpG island methylator phenotype (CIMP) is related to aberrant methylation in several genes, and is commonly observed in sporadic cases with DNA mismatch repair pathway deficient (dMMR) and MSI-high tumors.”
BackgroundInfluentialBrulé, S. Y., Jonker, D. J., Karapetis, C. S., O’Callaghan, C. J., Moore, M. J., Wong, R., Tebbutt, N. C., Underhill, C., Yip, D., Zalcberg, J. R., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.03.015 · Cited by 332 · cited 1×
“17 trial, LCRC patients benefited more from cetuximab therapy than RCRC patients [76].”
BackgroundBuerger, H., Otterbach, F., Simon, R., Poremba, C., Diallo, R., Decker, T., Riethdorf, L., Brinkschmidt, C., Dockhorn-Dworniczak, B., & Boecker, W. (1999) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199903)187:4<396::aid-path286>3.0.co;2-l · Cited by 328
Distinguishing right from left colon by the pattern of gene expression.
Glebov, O. K., Rodriguez, L. M., Nakahara, K., Jenkins, J., Cliatt, J., Humbyrd, C. J., DeNobile, J. W., Soballe, P. W., Simon, R., Wright, G. W., et al. (2003) · PubMed · Cited by 320
Colorectal cancer: Metastases to a single organ
Vatandoust, S. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i41.11767 · Cited by 308 · cited 4×
“Metastases in peritoneal region Liver and lung metastases [14, 15]”
BackgroundInfluentialChung, K. Y., Gore, I., Fong, L., Venook, A., Beck, S. B., Dorazio, P., Criscitiello, P. J., Healey, D. I., Huang, B., Gomez-Navarro, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3994 · Cited by 306 · cited 1×
“However, anti-CTLA-4 inhibitors did not show any significant benefit in CRC patients [89].”
BackgroundTwo colons‐two cancers: Paradigm shift and clinical implications
Gervaz, P., Bucher, P., & Morel, P. (2004) · Journal of Surgical Oncology · doi:10.1002/jso.20156 · Cited by 302 · cited 2×
“Understanding the characteristics of these two different entities is very important for developing effective therapies [21, 97].”
BackgroundNawa, T., Kato, J., Kawamoto, H., Okada, H., Yamamoto, H., Kohno, H., Endo, H., & Shiratori, Y. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.04923.x · Cited by 297 · cited 6×
“Difference Between Right Sided and Left Sided Colorectal Tumor [5-20]”
BackgroundInfluentialBishehsari, F. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i20.6055 · Cited by 265 · cited 1×
“Although the detection of CRC in the early stages is possible with routine colonoscopy screening, the prevalence is still increasing, especially in developing countries [95, 96].”
BackgroundPolo‐like kinase 1 (PLK1) is overexpressed in primary colorectal cancers
Takahashi, T., Sano, B., Nagata, T., Kato, H., Sugiyama, Y., Kunieda, K., Kimura, M., Okano, Y., & Saji, S. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01411.x · Cited by 265 · cited 1×
“For example, dysregulated expression of Aurora B and PLK highly correlated with CIN phenotype and advanced stages of CRC [49-51].”
BackgroundComprehensive molecular characterization of human colon and rectal cancer
McCullough, A. (2013) · Yearbook of Pathology and Laboratory Medicine · doi:10.1016/j.ypat.2012.11.050 · Cited by 261
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
Giannakis, M., Mu, X. J., Shukla, S. A., Qian, Z. R., Cohen, O., Nishihara, R., Bahl, S., Cao, Y., Amin-Mansour, A., Yamauchi, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.009 · Cited by 259
Imamura, Y., Morikawa, T., Liao, X., Lochhead, P., Kuchiba, A., Yamauchi, M., Qian, Z. R., Nishihara, R., Meyerhardt, J. A., Haigis, K. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3210 · Cited by 249 · cited 1×
“While KRAS codon 12 mutations are proposed to be associated with the increment in CRC-induced mortality, codon 13 mutations are not associated with survival [54].”
BackgroundAdjuvant Chemotherapy Use for Medicare Beneficiaries With Stage II Colon Cancer
Schrag, D., Rifas-Shiman, S., Saltz, L., Bach, P. B., & Begg, C. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.084 · Cited by 249 · cited 1×
“Although surgical resection is the primary option for all stages and adjuvant therapies seem to be effective in improving the survival among the patients [32, 100, 101], there is still a need for more effective therapies for both RCRC and LCRC stage IV patients.”
BackgroundThe Immune Biology of Microsatellite-Unstable Cancer
Kloor, M., & von Knebel Doeberitz, M. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.02.004 · Cited by 245 · cited 1×
“These tumors have highly activated lymphocytic microenvironment, and present a high degree of neoantigens [81].”
BackgroundKRAS mutation testing in metastatic colorectal cancer.
Tan, C., & Du, X. (2012) · PubMed · doi:10.3748/wjg.v18.i37.5171 · Cited by 227 · cited 1×
“KRAS mutations are found in 35-45% of CRC cases [53].”
BackgroundAntimetastatic Role of Smad4 Signaling in Colorectal Cancer
Zhang, B., Halder, S. K., Kashikar, N. D., Cho, Y., Datta, A., Gorden, D. L., & Datta, P. K. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.11.004 · Cited by 221
Boeckx, N., Koukakis, R., Op de Beeck, K., Rolfo, C., Van Camp, G., Siena, S., Tabernero, J., Douillard, J.-Y., André, T., & Peeters, M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx119 · Cited by 217
Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers
Salem, M. E., Weinberg, B. A., Xiu, J., El-Deiry, W. S., Hwang, J. J., Gatalica, Z., Philip, P. A., Shields, A. F., Lenz, H.-J., & Marshall, J. L. (2017) · Oncotarget · doi:10.18632/oncotarget.21169 · Cited by 216 · cited 1×
“Anti-EGFR therapies improved the overall survival in patients with left-sided KRAS wild type tumors, but not in patients with right-sided wild type tumors [79].”
BackgroundAdvances in the care of patients with mucinous colorectal cancer
Hugen, N., Brown, G., Glynne-Jones, R., de Wilt, J. H. W., & Nagtegaal, I. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.140 · Cited by 212 · cited 5×
“Mucinous adenocarcinomas, sessile serrated adenomas Tubular, villous adenocarcinomas [6, 10, 11]”
BackgroundInfluentialColorectal Cancer: Epidemiology, Risk Factors, and Health Services
Amersi, F., Agustin, M., & Ko, C. Y. (2005) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-2005-916274 · Cited by 199 · cited 2×
“However, villous adenomas, comprising only 5-10% of polyps have a high potential (35-40%) of malignancy [26].”
BackgroundGenetic Alterations During Colorectal-Tumor Development
Gresch, E. E. (1989) · Journal of Occupational and Environmental Medicine · doi:10.1097/00043764-198910000-00001 · Cited by 181
Mitotic Kinase Expression and Colorectal Cancer Progression
Katayama, H., Ota, T., Jisaki, F., Ueda, Y., Tanaka, T., Odashima, S., Suzuki, F., Terada, Y., & Tatsuka, M. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.13.1160 · Cited by 177 · cited 1×
“For example, dysregulated expression of Aurora B and PLK highly correlated with CIN phenotype and advanced stages of CRC [49-51].”
BackgroundPossible better long-term survival in left versus right-sided colon cancer - a systematic review.
Hansen, I. O., & Jess, P. (2012) · PubMed · Cited by 174
Immune Checkpoints as a Target for Colorectal Cancer Treatment
Passardi, A., Canale, M., Valgiusti, M., & Ulivi, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061324 · Cited by 173 · cited 4×
“Difference Between Right Sided and Left Sided Colorectal Tumor [5-20]”
BackgroundInfluentialReview of Histopathological and Molecular Prognostic Features in Colorectal Cancer
Marzouk, O., & Schofield, J. B. (2011) · Cancers · doi:10.3390/cancers3022767 · Cited by 167 · cited 4×
“Mucinous adenocarcinomas, sessile serrated adenomas Tubular, villous adenocarcinomas [6, 10, 11]”
BackgroundInfluentialMik, M., Berut, M., Dziki, Ł. A., Trzciński, R., & Dziki, A. J. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.58596 · Cited by 143 · cited 1×
“the right-sided CRC (RCRC) tumors arise from ascending colon, and proximal two thirds of the transverse colon and the left-sided CRC (LCRC) tumors arise from the descending and sigmoid colon, and distal one third of the transverse colon [5, 22].”
BackgroundGatalica, Z., Vranic, S., Xiu, J., Swensen, J., & Reddy, S. (2016) · Familial Cancer · doi:10.1007/s10689-016-9884-6 · Cited by 141 · cited 1×
“highly use these regulators as an anti-tumor immune response [82, 83].”
BackgroundDiaz, L. A., Marabelle, A., Delord, J.-P., Shapira-Frommer, R., Geva, R., Peled, N., Kim, T. W., Andre, T., Van Cutsem, E., Guimbaud, R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3071 · Cited by 125 · cited 1×
“The efficiency of pembrolizumab was evaluated with multi-centered KEYNOTE study that showed promising results in MSI-high tumors [91, 92].”
Background(2004) · Zeitschrift für Gastroenterologie · doi:10.1055/s-2004-812996 · Cited by 112
Kang, S. P., Gergich, K., Lubiniecki, G. M., de Alwis, D. P., Chen, C., Tice, M. A. B., & Rubin, E. H. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx076 · Cited by 110 · cited 1×
“The efficiency of pembrolizumab was evaluated with multi-centered KEYNOTE study that showed promising results in MSI-high tumors [91, 92].”
BackgroundAl-Mulla, F., Milner-White, E. J., Going, J. J., & Birnie, G. D. (1999) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199903)187:4<433::aid-path273>3.0.co;2-e · Cited by 110 · cited 1×
“KRAS mutations are commonly observed in Codon 12 and 13, resulting in constitutively active RAS protein, which in turn activates the downstream pathways leading to cell proliferation and cell survival [52].”
BackgroundJess, P., Hansen, I. O., Gamborg, M., & Jess, T. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-002608 · Cited by 102
Role of targeted therapy in metastatic colorectal cancer
Ohhara, Y., Fukuda, N., Takeuchi, S., Honma, R., Shimizu, Y., Kinoshita, I., & Dosaka-Akita, H. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i9.642 · Cited by 96 · cited 1×
“Systemic chemotherapy for CRC includes mainly fluoropyrimidines (5-fluorouracil (5-FU) and oral capecitabine), irinotecan, and oxaliplatin [69].”
BackgroundSasaki, K., Andreatos, N., Margonis, G. A., He, J., Weiss, M., Johnston, F., Wolfgang, C., Antoniou, E., Pikoulis, E., & Pawlik, T. M. (2016) · Journal of Surgical Oncology · doi:10.1002/jso.24425 · Cited by 96
Right Sided Colon Cancer as a Distinct Histopathological Subtype with Reduced Prognosis
Nitsche, U., Stögbauer, F., Späth, C., Haller, B., Wilhelm, D., Friess, H., & Bader, F. G. (2016) · Digestive Surgery · doi:10.1159/000443644 · Cited by 96 · cited 1×
“Right-sided CRC tumors are still detectable at an early stage, but with much more difficult than LCRC tumors because of their flat morphology [98, 99].”
BackgroundOne Colon Lumen but Two Organs
Carethers, J. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.029 · Cited by 95
Roth, A., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Archive ouverte UNIGE (University of Geneva) · Cited by 95
Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer
Boisen, M. K., Johansen, J. S., Dehlendorff, C., Larsen, J. S., Østerlind, K., Hansen, J., Nielsen, S. E., Pfeiffer, P., Tarpgaard, L. S., Holländer, N. H., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt253 · Cited by 92 · cited 1×
“However, most of the studies have shown that the prognosis of RCRC is worse than that of LCRC [29-31].”
Galon, J., Mlecnik, B., Marliot, F., Ou, F.-S., Bifulco, C. B., Lugli, A., Zlobec, I., Rau, T. T., Hartmann, A., Masucci, G. V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3500 · Cited by 87 · cited 1×
“Immunoscore is one of the new markers, which may be helpful for the prediction of immunotherapy responses [34].”
BackgroundJacob, B. J., Moineddin, R., Sutradhar, R., Baxter, N. N., & Urbach, D. R. (2012) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2012.03.247 · Cited by 85 · cited 1×
“Although the detection of CRC in the early stages is possible with routine colonoscopy screening, the prevalence is still increasing, especially in developing countries [95, 96].”
BackgroundMoritani, K., Hasegawa, H., Okabayashi, K., Ishii, Y., Endo, T., & Kitagawa, Y. (2014) · Surgery Today · doi:10.1007/s00595-013-0748-5 · Cited by 83 · cited 6×
“Difference Between Right Sided and Left Sided Colorectal Tumor [5-20]”
BackgroundResultInfluentialAdelstein, B., Dobbins, T., Harris, C. A., Marschner, I. C., & Ward, R. L. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.03.031 · Cited by 75 · cited 1×
“therapy, and not as a prognostic factor [58].”
BackgroundRight- and left-sided colorectal cancers respond differently to cetuximab
Wang, F., Bai, L., Liu, T.-S., Yu, Y.-Y., He, M.-M., Liu, K.-Y., Luo, H.-Y., Zhang, D.-S., Jin, Y., Wang, F.-H., et al. (2015) · Chinese Journal of Cancer · doi:10.1186/s40880-015-0022-x · Cited by 75
Weiss, J. M., Schumacher, J. R., Allen, G. O., Neuman, H. B., Lange, E. O., LoConte, N. K., Greenberg, C. C., & Smith, M. A. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3631-8 · Cited by 69 · cited 2×
“Although surgical resection is the primary option for all stages and adjuvant therapies seem to be effective in improving the survival among the patients [32, 100, 101], there is still a need for more effective therapies for both RCRC and LCRC stage IV patients.”
BackgroundTargeted Therapy of Colorectal Cancer
Seeber, A., & Gastl, G. A. (2016) · Oncology Research and Treatment · doi:10.1159/000453027 · Cited by 66
Familial Adenomatous Polyposis
Church, J. M. (2009) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2009.07.002 · Cited by 66
Staudacher, J. J., Bauer, J., Jana, A., Tian, J., Carroll, T., Mancinelli, G., Özden, Ö., Krett, N., Guzman, G., Kerr, D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05907-8 · Cited by 64 · cited 1×
“Activin is one of the essential components of TGF-β pathway, which induces a pro-metastatic phenotype in colorectal cancer cells [67].”
BackgroundPOLE somatic mutations in advanced colorectal cancer
Guerra, J., Pinto, C., Pinto, D., Pinheiro, M., Silva, R., Peixoto, A., Rocha, P., Veiga, I., Santos, C., Santos, R. P., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1245 · Cited by 61 · cited 1×
“polymerase epsilon (POLE) mutations have been observed in a small subset of microsatellite-stable and hypermutated CRCs that affects the proofreading activity of the enzyme, leading to the misincorporation of the bases during DNA replication [62].”
BackgroundSobrero, A. F., Guglielmi, A., Grossi, F., Puglisi, F., & Aschele, C. (2000) · PubMed · Cited by 57
Effects of Activin and TGFβ on p21 in Colon Cancer
Bauer, J., Sporn, J. C., Cabral, J., Gomez, J., & Jung, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039381 · Cited by 55 · cited 1×
“Activin also down-regulates p21, which is a cyclindependent kinase inhibitor and mediates p53-dependent cell cycle arrest, hence leading to more proliferative and invasive phenotype in colorectal cancer cells [68].”
BackgroundAljehani, M. A., Morgan, J. W., Guthrie, L., Jabo, B., Ramadan, M. M., Bahjri, K. A., Lum, S. S., Selleck, M. J., Reeves, M. E., Garberoglio, C. A., et al. (2017) · JAMA Surgery · doi:10.1001/jamasurg.2017.3466 · Cited by 53 · cited 1×
“While the combination of bevacizumab and systemic chemotherapy reduced the mortality in both RCRC and LCRC patients, the combination of cetuximab and systemic chemotherapy was shown to be effective only in LCRC patients [80].”
BackgroundSessile serrated adenoma: From identification to resection
Bordaçahar, B., Barret, M., Terris, B., Dhooge, M., Dréanic, J., Prat, F., Coriat, R., & Chaussade, S. (2014) · Digestive and Liver Disease · doi:10.1016/j.dld.2014.09.006 · Cited by 47 · cited 4×
“They are frequently observed in RCRC and MSI-high tumors [10].”
BackgroundInfluentialPD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer
Sclafani, F. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30512-0 · Cited by 44
Molecular Mechanisms of Colorectal Carcinogenesis
Roper, J., & Hung, K. E. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8412-7_2 · Cited by 30
Colonic Adenomatous Polyposis Syndromes: Clinical Management
Ellis, C. (2008) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0028-1089940 · Cited by 29 · cited 1×
“Most of the CRC (about 70%) tend to occur in the left side, whereas, a small percentage (about 10%) occurs in the right side [38, 39].”
BackgroundEpidemiology of Colorectal Cancer — Incidence, Lifetime Risk Factors Statistics and Temporal Trends
Thélin, C. S., & Sikka, S. (2015) · InTech eBooks · doi:10.5772/61945 · Cited by 28
Clinical implications of BRAF mutation test in colorectal cancer.
Mojarad, E. N., Farahani, R. K., Haghighi, M. M., Aghdaei, H. A., Kuppen, P. J. K., & Zali, M. R. (2013) · Gastroenterology and hepatology from bed to bench. · Cited by 27
Microsatellite Instability in Colorectal Cancer
Nojadeh, J. N., Sharif, S. B., & Sakhinia, E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005253422111 · Cited by 20
Adjuvant Chemotherapy for Stage II Colon Cancer: The Debate Goes On
Lee, J. J., & Chu, E. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.022178 · Cited by 19 · cited 1×
“While assays such as Oncotype DX or ColoPrint can predict the recurrence rates among stage II patients, they still have a limited role in predicting the therapy responses among these patients [33].”
MethodFlat elevated lesions of the colon and rectum: a spectrum of neoplastic and nonneoplastic entities
Gualco, G., Reissenweber, N. J., Cliché, I., & Bacchi, C. E. (2006) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2006.03.003 · Cited by 17 · cited 4×
“Difference Between Right Sided and Left Sided Colorectal Tumor [5-20]”
BackgroundInfluentialGeneration of activin receptor type IIB isoform‐specific hypomorphic alleles
Lee, Y. J., Hong, K., Yun, J., & Oh, S. P. (2006) · genesis · doi:10.1002/dvg.20238 · Cited by 16
Bibeau, F. (2016) · Côlon & Rectum · doi:10.1007/s11725-016-0664-4 · Cited by 12
Pole Somatic Mutations in Advanced Colorectal Cancer
Guerra, J. S. G. (2015) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/d13j-b519 · Cited by 7
Cited by
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
Morris, V. K., Kennedy, E. B., Baxter, N. N., Benson, A. B., Cercek, A., Cho, M., Ciombor, K. K., Cremolini, C., Davis, A., Deming, D. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01690 · Cited by 682
“fluorouracil (FU)–based chemotherapy, and more recently, targeted therapies have been developed for specific molecular subtypes and primary tumor sidedness.(6) This guideline provides a review of the evidence for areas of uncertainty in the treatment of mCRC, including indications for targeted therapy, and treatment o…”
BackgroundPrognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges
Koncina, E., Haan, S., Rauh, S., & Letellier, E. (2020) · Cancers · doi:10.3390/cancers12020319 · Cited by 259
“Additionally, the two parts of the colon have different blood supplies, distinct microbiome populations and are associated with different biological features [80].”
BackgroundInfluentialSmoking and Colorectal Cancer Risk, Overall and by Molecular Subtypes: A Meta-Analysis
Botteri, E., Borroni, E., Sloan, E. K., Bagnardi, V., Bosetti, C., Peveri, G., Santucci, C., Specchia, C., van den Brandt, P., Gallus, S., et al. (2020) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000803 · Cited by 229
“MSI-high CRC occurs in the proximal part of the colon and with increased frequency in women (34).”
BackgroundSwain, C. K. (2024) · Discover Environment · doi:10.1007/s44274-024-00030-8 · Cited by 165
“Growing awareness of ever-expanding industrialization as well as intensive agricultural soil use and their influence on the content of heavy metals in the soil necessitates the appropriate evaluation as well as determination of their ecological risk [54, 55].”
The microbial landscape of colorectal cancer
White, M. T., & Sears, C. L. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00973-4 · Cited by 161
“The vast majority of CRCs begin as precursor lesions called polyps, formed by clonal colonic epithelial cell expansion 87 .”
Influential
Metadata
- Authors
- Baran, B., Mert Ozupek, N., Yerli Tetik, N., Acar, E., Bekcioglu, O., & Baskin, Y.
- Affiliations
- Dokuz Eylül University (TR)
- ORCID
- Acar, Emine
- Venue
- Gastroenterology Research
- Publisher
- Elmer Press, Inc.
- Published
- 2018
- Volume
- 11
- Issue
- 4
- Pages
- 264-273
- ISSN
- 1918-2805 (ISSN-L)
- 1918-2813
- PMC
- PMC6089587
- OpenAlex
- W2887365295
- Cited by
- 553
- References
- 113
- Citations by year
- 2026: 62 · 2025: 59 · 2024: 117 · 2023: 76 · 2022: 66 · 2021: 90 · 2020: 56 · 2019: 25 · 2018: 2
- FWCI
- 4.52
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- Locations
- Gastroenterology Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- left-sided colorectal cancer, right-sided colorectal cancer, tumor location, mismatch repair deficiency, chromosomal instability, KRAS mutation, APC mutation, PIK3CA mutation, TP53 mutation, adjuvant chemotherapy, 5-fluorouracil, anti-EGFR therapy, immunotherapy, prognosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.